Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.
BOSTON (Reuters) - Teva Pharmaceuticals has filed a patent infringement lawsuit seeking to block Eli Lilly and Company from bringing its migraine drug galcanezumab to market in the United States.
In the lawsuit on Tuesday in federal court in Boston, Teva said Lilly’s planned drug would infringe five patents that cover the Israeli drugmaker’s own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.
Teva said Indianapolis-based Lilly was aware of the patents covering its drug, fremanezumab, but was nonetheless seeking to launch its competing galcanezumab product as soon as it received FDA approval.
